JP2023518395A5 - - Google Patents
Info
- Publication number
- JP2023518395A5 JP2023518395A5 JP2022555909A JP2022555909A JP2023518395A5 JP 2023518395 A5 JP2023518395 A5 JP 2023518395A5 JP 2022555909 A JP2022555909 A JP 2022555909A JP 2022555909 A JP2022555909 A JP 2022555909A JP 2023518395 A5 JP2023518395 A5 JP 2023518395A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- reverse transcriptase
- inventions
- composition according
- guide nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992032P | 2020-03-19 | 2020-03-19 | |
| US62/992,032 | 2020-03-19 | ||
| US202063055829P | 2020-07-23 | 2020-07-23 | |
| US63/055,829 | 2020-07-23 | ||
| US202163153161P | 2021-02-24 | 2021-02-24 | |
| US63/153,161 | 2021-02-24 | ||
| PCT/US2021/023041 WO2021188840A1 (en) | 2020-03-19 | 2021-03-18 | Methods and compositions for directed genome editing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518395A JP2023518395A (ja) | 2023-05-01 |
| JP2023518395A5 true JP2023518395A5 (https=) | 2024-03-29 |
Family
ID=77747638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555909A Pending JP2023518395A (ja) | 2020-03-19 | 2021-03-18 | 指向性ゲノム編集のための方法及び組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11352623B2 (https=) |
| EP (1) | EP4121522A4 (https=) |
| JP (1) | JP2023518395A (https=) |
| KR (1) | KR20230003467A (https=) |
| CN (1) | CN115667505A (https=) |
| AU (1) | AU2021236683A1 (https=) |
| MX (1) | MX2022011562A (https=) |
| WO (1) | WO2021188840A1 (https=) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11649442B2 (en) | 2017-09-08 | 2023-05-16 | The Regents Of The University Of California | RNA-guided endonuclease fusion polypeptides and methods of use thereof |
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| EP3847254A4 (en) | 2018-09-07 | 2022-08-10 | Beam Therapeutics Inc. | COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM |
| WO2020051562A2 (en) | 2018-09-07 | 2020-03-12 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| AU2020215730A1 (en) | 2019-01-31 | 2021-07-29 | Beam Therapeutics Inc. | Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors |
| CN120174005A (zh) | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CN116209756A (zh) | 2020-03-04 | 2023-06-02 | 旗舰先锋创新Vi有限责任公司 | 调控基因组的方法和组合物 |
| JP2023518395A (ja) | 2020-03-19 | 2023-05-01 | インテリア セラピューティクス，インコーポレイテッド | 指向性ゲノム編集のための方法及び組成物 |
| IL297761A (en) * | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence |
| CA3189601A1 (en) | 2020-07-24 | 2022-01-27 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| CA3196831A1 (en) | 2020-09-25 | 2022-03-31 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| EP4232583A1 (en) | 2020-10-21 | 2023-08-30 | Massachusetts Institute of Technology | Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste) |
| US20240026381A1 (en) * | 2020-11-03 | 2024-01-25 | The Board Of Trustees Of The University Of Illinois | Split prime editing platforms |
| WO2023288332A2 (en) * | 2021-07-16 | 2023-01-19 | Prime Medicine, Inc. | Genome editing compositions and methods for treatment of wilson's disease |
| EP4392039A4 (en) * | 2021-08-24 | 2025-10-15 | Prime Medicine Inc | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATING RETINOPATHY |
| AU2022343268A1 (en) | 2021-09-08 | 2024-03-28 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
| EP4413128A1 (en) * | 2021-10-08 | 2024-08-14 | The General Hospital Corporation | Improved crispr prime editors |
| EP4419688A2 (en) * | 2021-10-21 | 2024-08-28 | Prime Medicine, Inc. | Genome editing compositions and methods for treatment of usher syndrome type 3 |
| JP2024543481A (ja) * | 2021-11-12 | 2024-11-21 | リプレイス セラピューティクス リミテッド ライアビリティ カンパニー | 直接置き換えゲノム編集 |
| US11866728B2 (en) | 2022-01-21 | 2024-01-09 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| AU2023293131A1 (en) | 2022-06-16 | 2024-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for reducing mhc class i in a cell |
| CN115029374B (zh) * | 2022-06-24 | 2023-12-26 | 安徽省农业科学院水稻研究所 | 一种用于骨干载体的pegRNA表达框及相应骨干载体和应用 |
| JP2025525569A (ja) | 2022-07-18 | 2025-08-05 | レナゲード セラピューティクス マネージメント インコーポレイテッド | 遺伝子編集成分、システム、及び使用方法 |
| CA3265664A1 (en) | 2022-08-25 | 2024-02-29 | Life Edit Therapeutics, Inc. | CHEMICAL MODIFICATION OF GUIDE RNA WITH A LOCKED NUCLEIC ACID FOR RNA-GUIDED NUCLEASE-MEDIATED GENE EDITING |
| KR20250126155A (ko) | 2022-11-04 | 2025-08-22 | 라이프 에디트 테라퓨틱스, 인크. | 내부 삽입 부위를 갖는 진화된 아데닌 데아미나제 및 rna-가이드 뉴클레아제 융합 단백질 및 사용 방법 |
| EP4634383A1 (en) | 2022-12-16 | 2025-10-22 | Life Edit Therapeutics, Inc. | Guide rnas that target foxp3 gene and methods of use |
| WO2024127370A1 (en) | 2022-12-16 | 2024-06-20 | LifeEDIT Therapeutics, Inc. | Guide rnas that target trac gene and methods of use |
| WO2024178397A2 (en) | 2023-02-24 | 2024-08-29 | Elevatebio Technologies, Inc. | Modified immune effector cells and methods of use |
| WO2025022367A2 (en) | 2023-07-27 | 2025-01-30 | Life Edit Therapeutics, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| IL326191A (en) | 2023-08-14 | 2026-03-01 | Intellia Therapeutics Inc | Compositions and methods for genetic modification of transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025038646A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Cd70 car-t compositions and methods for cell-based therapy |
| WO2025038642A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying cd70 |
| AU2024335327A1 (en) | 2023-09-01 | 2026-03-26 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| WO2025076306A1 (en) * | 2023-10-06 | 2025-04-10 | University Of Massachusetts | Prime editors having improved prime editing efficiency |
| WO2025081111A1 (en) * | 2023-10-12 | 2025-04-17 | The University Of Chicago | Methods and compositions for characterizing rna-binding protein binding sites by in-situ reverse transcription-based sequencing |
| WO2025083619A1 (en) | 2023-10-18 | 2025-04-24 | Life Edit Therapeutics, Inc. | Rna-guided nucleases and acive fragments and variants thereof and methods of use |
| WO2025106766A1 (en) * | 2023-11-15 | 2025-05-22 | Yale University | Fusion-modified enzyme constructs |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025155753A2 (en) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Improved gene editing system, guides, and methods |
| WO2025174908A1 (en) | 2024-02-12 | 2025-08-21 | Life Edit Therapeutics, Inc. | Novel rna-guided nucleases and proteins for polymerase editing |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025226730A1 (en) * | 2024-04-22 | 2025-10-30 | Transit Therapeutics, Inc. | Revision of genetic material using direct replacement editing |
| WO2025235506A2 (en) * | 2024-05-06 | 2025-11-13 | Flagship Pioneering Innovations Vi, Llc | Atp7b-modulating compositions and methods |
| WO2025255308A1 (en) | 2024-06-07 | 2025-12-11 | Intellia Therapeutics, Inc. | Cd8 co-receptor chimeric polypeptides in tcr cell therapy |
| WO2025264736A1 (en) * | 2024-06-18 | 2025-12-26 | Blake Richards | Logic capable protease probes and uses thereof |
| WO2026003754A1 (en) | 2024-06-25 | 2026-01-02 | Life Edit Therapeutics, Inc. | Novel reverse transcriptases and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69923274T2 (de) * | 1998-10-12 | 2006-03-30 | Roche Diagnostics Gmbh | Deoxynukleotidtriphosphatkinase aus Insektenzellen zur Synthese von Nukleosidmonophosphaten |
| GB0806562D0 (en) * | 2008-04-10 | 2008-05-14 | Fermentas Uab | Production of nucleic acid |
| WO2011116184A2 (en) | 2010-03-17 | 2011-09-22 | Cornell University | Methods and compositions for targeted mutagenesis in bacteria |
| FR2973040B1 (fr) * | 2011-03-23 | 2016-04-15 | Centre Nat De La Rech Scient (C N R S) | Methode de criblage de composes antiretroviraux et vaccin |
| US9161995B2 (en) | 2011-07-25 | 2015-10-20 | Sangamo Biosciences, Inc. | Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| RU2662932C2 (ru) * | 2013-03-14 | 2018-07-31 | Карибо Биосайенсиз, Инк. | Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты |
| WO2014186686A2 (en) | 2013-05-17 | 2014-11-20 | Two Blades Foundation | Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases |
| WO2015021426A1 (en) | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | A crispr/cas system-based novel fusion protein and its application in genome editing |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| US9963687B2 (en) | 2014-08-27 | 2018-05-08 | New England Biolabs, Inc. | Fusion polymerase and method for using the same |
| EP3188763B1 (en) | 2014-09-02 | 2020-05-13 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification |
| EP3201340B1 (en) * | 2014-10-01 | 2020-12-02 | The General Hospital Corporation | Methods for increasing efficiency of nuclease-induced homology-directed repair |
| CN107614680A (zh) | 2015-05-14 | 2018-01-19 | 南加利福尼亚大学 | 利用重组核酸内切酶系统的最佳化基因编辑 |
| CA3001683C (en) | 2015-06-05 | 2024-06-04 | The Regents Of The University Of California | Methods and compositions for generating crispr/cas guide rnas |
| LT3505174T (lt) * | 2015-06-17 | 2020-09-10 | The Trustees Of Columbia University In The City Of New York | Deoksinukleozidų terapija, skirta gydyti ligas, kurias sukelia nesubalansuoti nukleotidų kiekiai, įskaitant mitochondrinės dnr išsekimo sindromus |
| US9926546B2 (en) | 2015-08-28 | 2018-03-27 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| EP3163302A1 (en) * | 2015-11-02 | 2017-05-03 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Samhd1 modulation for treating resistance to cancer therapy |
| WO2017106616A1 (en) | 2015-12-17 | 2017-06-22 | The Regents Of The University Of Colorado, A Body Corporate | Varicella zoster virus encoding regulatable cas9 nuclease |
| US11447768B2 (en) | 2016-03-01 | 2022-09-20 | University Of Florida Research Foundation, Incorporated | Molecular cell diary system |
| EP3426353A4 (en) * | 2016-03-09 | 2020-05-06 | The University of Massachusetts | USE OF MODIFIED HIV-1 TO GENERATE FULLY HUMAN ANTIBODIES |
| AU2017257274B2 (en) | 2016-04-19 | 2023-07-13 | Massachusetts Institute Of Technology | Novel CRISPR enzymes and systems |
| CN110214183A (zh) | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
| ES2985812T3 (es) * | 2016-09-09 | 2024-11-07 | The Board Of Trustees Of The Leland Stanfordjunior Univ | Edición genómica de precisión de alto rendimiento |
| KR20190098747A (ko) * | 2016-12-05 | 2019-08-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료법을 위한 조작된 세포의 제조방법 |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| US11649442B2 (en) | 2017-09-08 | 2023-05-16 | The Regents Of The University Of California | RNA-guided endonuclease fusion polypeptides and methods of use thereof |
| WO2019070843A1 (en) * | 2017-10-03 | 2019-04-11 | Board Of Regents, The University Of Texas System | INVERSE TRANSCRIPTASE WITH LTR-FREE BACKLIGHTS AND USES THEREOF |
| CA3105925A1 (en) * | 2018-07-10 | 2020-01-16 | Alia Therapeutics S.R.L. | Vesicles for traceless delivery of guide rna molecules and/or guide rna molecule/rna-guided nuclease complex(es) and a production method thereof |
| EP3844272A1 (en) * | 2018-08-28 | 2021-07-07 | Flagship Pioneering Innovations VI, LLC | Methods and compositions for modulating a genome |
| EP3847254A4 (en) * | 2018-09-07 | 2022-08-10 | Beam Therapeutics Inc. | COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM |
| WO2020191233A1 (en) * | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| JP2023518395A (ja) | 2020-03-19 | 2023-05-01 | インテリア セラピューティクス，インコーポレイテッド | 指向性ゲノム編集のための方法及び組成物 |
-
2021
- 2021-03-18 JP JP2022555909A patent/JP2023518395A/ja active Pending
- 2021-03-18 KR KR1020227035994A patent/KR20230003467A/ko active Pending
- 2021-03-18 EP EP21771405.4A patent/EP4121522A4/en active Pending
- 2021-03-18 WO PCT/US2021/023041 patent/WO2021188840A1/en not_active Ceased
- 2021-03-18 CN CN202180035786.9A patent/CN115667505A/zh active Pending
- 2021-03-18 AU AU2021236683A patent/AU2021236683A1/en active Pending
- 2021-03-18 MX MX2022011562A patent/MX2022011562A/es unknown
- 2021-03-19 US US17/206,526 patent/US11352623B2/en active Active
- 2021-03-19 US US17/206,522 patent/US11193123B2/en active Active
- 2021-10-20 US US17/506,419 patent/US20220090064A1/en not_active Abandoned
-
2022
- 2022-05-03 US US17/735,929 patent/US20230076357A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023518395A5 (https=) | ||
| US11193123B2 (en) | Methods and compositions for directed genome editing | |
| AU2019255798A1 (en) | Fusion proteins and fusion ribonucleic acids for tracking and manipulating cellular RNA | |
| ES2745769T3 (es) | Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10) | |
| ES2314093T3 (es) | Cebador para el control de la reasociacion y sus usos. | |
| JP2019196400A5 (https=) | ||
| AU2016244033A1 (en) | CRISPR/CAS-related methods and compositions for treating Duchenne Muscular Dystrophy and Becker Muscular Dystrophy | |
| Buzdin | Retroelements and formation of chimeric retrogenes | |
| JP2019525759A5 (https=) | ||
| TW202320810A (zh) | Ｐａｈ調節組合物及方法 | |
| KR20210102209A (ko) | 알파-1 항트립신 결핍증을 치료하기 위한 조성물 및 방법 | |
| JP2022523719A (ja) | Ａａｖキャプシドの転写依存性定方向進化を使用するための方法 | |
| TW202329988A (zh) | 調節cftr之組合物及方法 | |
| US20250025572A1 (en) | Engineered crispr/cas12a effector proteins, and uses thereof | |
| Yu et al. | Sequence and in vitro expression of the M2 gene of turkey rhinotracheitis pneumovirus | |
| CN111447954A (zh) | 用于恢复hbb基因功能的腺相关病毒组合物及其使用方法 | |
| AU2020262281A1 (en) | Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof | |
| KR20250089534A (ko) | 역전사효소를 포함하는 유전자 편집 시스템 | |
| CA3235195A1 (en) | Gene therapy for the treatment of wilson's disease | |
| CN118355118A (zh) | 用于治疗α-1抗胰蛋白酶缺乏症的组合物和方法 | |
| Damert | LINE-1 ORF1p does not determine substrate preference for human/orangutan SVA and gibbon LAVA | |
| WO2025106853A1 (en) | Cas12a nickase proteins and uses thereof | |
| JP2006296350A (ja) | 複数の核酸を連結した核酸構築物の作製方法および該方法を利用した核酸のクローニング | |
| WO2024226065A1 (en) | Manufacturing and use of recombinant self-complementary aav vectors | |
| WO2024223931A1 (en) | Manufacturing and use of recombinant self-complementary aav vectors |